Transcriptomic data can guide the development of targeted therapies by identifying specific genes or pathways that are dysregulated in a particular cancer type. For example, the identification of the overexpression of the HER2 gene in certain breast cancers has led to the development of HER2-targeted therapies like trastuzumab.
